Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K7 | O14733 | 3/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | BTK | Q06187 | 6/20 | 0.51 |
| ▸ | JAK3 | P52333 | 5/20 | 0.51 |
| ▸ | JAK1 | P23458 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 2/20 | 0.45 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23722543 | 0.75 | AURKA (1.00) | MAP2K7AURKABTKJAK3JAK1 | |
| SCHEMBL30935156 | 0.74 | TGM2 (0.53) | MAP2K7AURKABTKJAK3JAK1 | |
| SCHEMBL23721801 | 0.73 | AURKA (0.71) | MAP2K7AURKABTKJAK3JAK1 | |
| Acetic Acid SCHEMBL15622681 | 0.72 | KMT2A (0.57) | NAMPT | |
| SCHEMBL24150191 | 0.72 | JAK3 (0.51) | MAP2K7AURKABTKJAK3JAK1 | |
| SCHEMBL30190875 | 0.72 | JAK3 (0.51) | MAP2K7AURKABTKJAK3JAK1 | |
| SCHEMBL24150517 | 0.72 | JAK3 (0.51) | MAP2K7AURKABTKJAK3JAK1 | |
| SCHEMBL30190722 | 0.72 | JAK3 (0.51) | MAP2K7AURKABTKJAK3JAK1 | |
| SCHEMBL30446277 | 0.72 | BTK (0.61) | MAP2K7AURKABTKTGM2EGFR | |
| SCHEMBL26911085 | 0.72 | BTK (0.61) | MAP2K7AURKABTKTGM2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238173-A1 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 INHIBITORS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238173-A1 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 INHIBITORS | MAPK7, MAP2K7, MAP3K7 | MAP2K7 2/4885AURKA 340/4885BTK 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.